{{Link style|time=2015-12-11T06:12:11+00:00}}
{{roughtranslation|time=2012-06-13T16:54:59+00:00}}
{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 458775891
| IUPAC_name = 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one
| image = Didanosin.svg
| width = 220

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|didanosine}}
| MedlinePlus = a691006
| pregnancy_AU = B2
| pregnancy_US = B
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 30 to 54%
| protein_bound = Less than 5%
| elimination_half-life = 1.5 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 69655-05-6
| ATC_prefix = J05
| ATC_suffix = AF02
| ATC_supplemental =  
| PubChem = 50599
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00900
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 45864
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = K3GDH6OH08
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00296
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 490877
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1460
| NIAID_ChemDB = 000004

<!--Chemical data-->
 | C=10 | H=12 | N=4 | O=3 
| molecular_weight = 236.227 g/mol
| smiles = O=C3/N=C\Nc1c3ncn1[C@@H]2O[C@@H](CC2)CO
| InChI = 1/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
| InChIKey = BXZVVICBKDXVGW-NKWVEPMBBL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BXZVVICBKDXVGW-NKWVEPMBSA-N
}}
'''地达诺新'''（{{lang-en|Didanosine}}，化学名为'''2',3'-双脱氧腺苷'''，简称为'''ddI'''或'''DDI'''）是[[反轉錄酶抑制劑|反轉錄酶抑制劑]]，能有效的對抗HIV病毒，常跟其他的[[抗反轉錄病毒藥物|抗反轉錄病毒藥物]]一起使用，用于[[高效抗反轉錄病毒治療|高效抗反轉錄病毒治療]]（[[:en:Highly_Active_Anti-Retroviral_Therapy|Highly Active Anti-Retroviral Therapy]]，HAART）

== 作用機轉 ==
地达诺新是[[鳥苷|鳥苷]]的[[核酸|核酸]]類似物（[[:en:nucleoside_analogue|nucleoside analogue]]）。它跟其它的核酸類似物有所不同，因為它不是接一般常見的鹼基，接於醣上的是[[次黃嘌呤|次黃嘌呤]]。在細胞中，去羟肌苷會被細胞酵素磷酸化轉成它的[[活性代謝物|活性代謝物]][[雙脫氧腺苷三磷酸|雙脫氧腺苷三磷酸]]（dideoxyadenosine triphosphate，ddATP）。跟其它的抗HIV核酸類似物的機轉一樣，它會跟[[去氧腺苷三磷酸|去氧腺苷三磷酸]]競爭，而中斷反轉錄酶的作用且會併入到病毒的DNA而使DNA鏈斷裂。

== 副作用 ==
常見的副作用有[[腹瀉|腹瀉]]、[[噁心|噁心]][[嘔吐|嘔吐]]、[[腹痛|腹痛]]、[[發燒|發燒]]、[[頭痛|頭痛]]跟[[紅疹|紅疹]]。地达诺新的試驗中，有21～26%的試驗者發生[[周邊神經炎|周邊神經炎]]（[[:en:Peripheral_neuropathy|Peripheral neuropathy]]）。<ref name="Peripheral neuropathy">[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=VIDEX VIDEX (didanosine): chewable/dispersible buffered tablets; buffered powder for oral solution; pediatric powder for oral solution. Product information (July 2000)]。</ref>

[[胰臟炎|胰臟炎]]雖然不常見，但卻會造成突然的死亡。

== 參考資料 ==
{{reflist}}

{{抗逆转录病毒药物}}

{{DEFAULTSORT:Didanosin}}
[[Category:核苷类似物逆转录酶抑制剂|Category:核苷类似物逆转录酶抑制剂]]
[[Category:嘌呤|Category:嘌呤]]
[[Category:百时美施贵宝|Category:百时美施贵宝]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]